

Retinal Biologics Market - 2024-2033

<https://marketpublishers.com/r/R9895699F771EN.html>

Date: May 2025

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: R9895699F771EN

Abstracts

The Retinal Biologics Market was valued at US\$ 24.16 Billion in 2024 and is anticipated to reach US\$ 40.46 Billion by 2033, at a CAGR of 0.059 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Retinal Biologics Market.

This report delivers a comprehensive overview of the Retinal Biologics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Retinal Biologics Market. The Retinal Biologics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Retinal Biologics Market Scope:

Key Players

Bayer AG

Major Highlights

This report delivers a comprehensive overview of the Retinal Biologics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Retinal Biologics Market. The Retinal Biologics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

- 3.1. Key Trends and Future Projections

4. SNIPPET BY DRUG CLASS

- 4.1. Snippet by Indication
- 4.2. Snippet by Route of Administration
- 4.3. Snippet by Distribution Channel
- 4.4. Snippet by Region

5. DYNAMICS

5.1. Impacting Factors

5.1.1. Drivers

- 5.1.1.1. Rising Prevalence of Retinal Disorders
- 5.1.1.2. Rise of Novel Techniques in Research and Development
- 5.1.1.3. XX

5.1.2. Restraints

- 5.1.2.1. Limited Patient Compliance due to Invasive Treatment Methods
- 5.1.2.2. Regulatory Challenges
- 5.1.2.3. XX

5.1.3. Opportunity

- 5.1.3.1. Emerging Biologic Therapies
- 5.1.3.2. XX

5.1.4. Impact Analysis

6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 6.1. Market Leaders and Pioneers
 - 6.1.1. Emerging Pioneers and Prominent Players
 - 6.1.2. Established leaders with largest largest-selling Brand
 - 6.1.3. Market leaders with established products & Services
- 6.2. CXO Perspectives
- 6.3. Latest Developments and Breakthroughs
- 6.4. Case Studies/Ongoing Research
- 6.5. Regulatory and Reimbursement Landscape
 - 6.5.1. North America
 - 6.5.2. Europe
 - 6.5.3. Asia Pacific
 - 6.5.4. South America
 - 6.5.5. Middle East & Africa
- 6.6. Porter's Five Force Analysis
- 6.7. Supply Chain Analysis
- 6.8. Patent Analysis
- 6.9. SWOT Analysis
- 6.10. Unmet Needs and Gaps
- 6.11. Recommended Strategies for Market Entry and Expansion
- 6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 6.13. Pricing Analysis and Price Dynamics
- 6.14. Key Opinion Leaders

7. GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Anti-VEGF Drugs*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 7.2.3. Aflibercept
 - 7.2.4. Ranibizumab
 - 7.2.5. Bevacizumab
 - 7.2.6. Brolucizumab
- 7.3. Corticosteroids
 - 7.3.1. Dexamethasone
 - 7.3.2. Fluocinolone Acetonide
- 7.4. Others

8. GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.1.2. Market Attractiveness Index, By Indication

8.2. Age-related Macular Degeneration (AMD)*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)?

8.3. Diabetic Retinopathy (DR)

8.4. Retinal Vein Occlusion (RVO)

8.5. Uveitis

8.6. Others

9. GLOBAL RETINAL BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.1.2. Market Attractiveness Index, By Route of Administration

9.2. Intravitreal*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Systemic

10. GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.1.2. Market Attractiveness Index, By Distribution Channel

10.2. Hospital Pharmacies*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Retail Pharmacies

10.4. Online Pharmacies

11. RETINAL BIOLOGICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

12. INTRODUCTION

12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

12.1.1. Market Attractiveness Index, By Region

12.2. North America

12.2.1. Introduction

12.2.2. Key Region-Specific Dynamics

12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.2.7.1. U.S.

12.2.7.2. Canada

12.2.7.3. Mexico

12.3. Europe

12.3.1. Introduction

12.3.2. Key Region-Specific Dynamics

12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.3.7.1. Germany

12.3.7.2. U.K.

12.3.7.3. France

12.3.7.4. Spain

12.3.7.5. Italy

12.3.7.6. Rest of Europe

12.4. South America

12.4.1. Introduction

12.4.2. Key Region-Specific Dynamics

12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.4.7.1. Brazil

12.4.7.2. Argentina

12.4.7.3. Rest of South America

12.5. Asia-Pacific

12.5.1. Introduction

12.5.2. Key Region-Specific Dynamics

12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12.5.7.1. China

12.5.7.2. India

12.5.7.3. Japan

12.5.7.4. South Korea

12.5.7.5. Rest of Asia-Pacific

12.6. Middle East and Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

14. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

14.1. Market Share Analysis and Positioning Matrix

14.2. Strategic Partnerships, Mergers & Acquisitions

14.3. Key Developments in Drug Class Portfolios and Innovations

14.4. Company Benchmarking

15. COMPANY PROFILES

15.1. Bayer AG*

- 15.1.1. Company Overview
- 15.1.2. Drug Class Portfolio
 - 15.1.2.1. Drug Class Description
 - 15.1.2.2. Drug Class Key Performance Indicators (KPIs)
 - 15.1.2.3. Historic and Forecasted Drug Class Sales
 - 15.1.2.4. Drug Class Sales Volume

16. FINANCIAL OVERVIEW

- 16.1. Company Revenue
 - 16.1.1. Geographical Revenue Shares
 - 16.1.1.1. Revenue Forecasts
 - 16.1.2. Key Developments
 - 16.1.2.1. Mergers & Acquisitions
 - 16.1.2.2. Key Drug Class Development Activities
 - 16.1.2.3. Regulatory Approvals, etc.
 - 16.1.3. SWOT Analysis
- 16.2. F. Hoffmann-La Roche Ltd
- 16.3. Regeneron Pharmaceuticals Inc
- 16.4. Oxurion NV
- 16.5. Chengdu Kanghong Biotech
- 16.6. Novartis International AG
- 16.7. Intas Pharmaceuticals Ltd
- 16.8. Samsung Bioepis (*LIST NOT EXHAUSTIVE)

17. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 17.1. Data Collection Methods
- 17.2. Data Triangulation
- 17.3. Forecasting Techniques
- 17.4. Data Verification and Validation

18. APPENDIX

- 18.1. About Us and Services
- 18.2. Contact Us

I would like to order

Product name: Retinal Biologics Market - 2024-2033

Product link: <https://marketpublishers.com/r/R9895699F771EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R9895699F771EN.html>